LAV

Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board

June 29, 2026

Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in...

IMPACT Therapeutics (07630.HK) Lists on HKEX Main Board

May 13, 2026

May 13, 2026 – IMPACT Therapeutics, Inc. (“IMPACT Therapeutics” or the “Company”), a commercial...

Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round

April 21, 2026

NEW YORK, April 20, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for...

Syneron Bio Announces Completion of $150 Million Series B Financing

March 31, 2026

Beijing, March 30，2026 — Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide...

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

March 17, 2026

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of...

Ronovo Surgical advances commercialization in China through Targeted Collaboration Agreement with Johnson & Johnson

September 6, 2025

Shanghai, China – September 5, 2025 – Ronovo Surgical, a global innovator in next-generation...

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

April 11, 2025

Shanghai, China, April 10, 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced...

Syneron Bio Announces Strategic Collaboration with AstraZeneca

March 21, 2025

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug...

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

January 17, 2025

SHANGHAI, January 16th, 2025 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

January 13, 2025

[January 13, 2025] – Cornerstone Robotics (the “Company”), a leading global innovator in surgical...

Alebund Pharmaceutical announced the first closing of RMB 550 million in Series C financing

January 7, 2025

January 7, 2025, Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated...

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

December 18, 2024

MIAMI--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today...

AGAMREE® for DMD Treatment was Approved by China’s NMPA

December 11, 2024

December 11, 2024, Sperogenix Therapeutics announced that, AGAMREE® (vamorolone) was approved by...

Duality Biologics and GSK Enter into Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)

December 4, 2024

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics (...

IMPACT Announces Completion of RMB 250 million Sr. D++ Financing

November 15, 2024

SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

October 29, 2024

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B...

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

September 30, 2024

Cambridge, Massachusetts, September 30, 2024 - Regor Pharmaceuticals (USA) ("Regor") has entered...

ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

August 2, 2024

Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ...

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

July 19, 2024

- Financing led by LongRiver Investments with participation by new and existing global...

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

June 13, 2024

- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the...

All Categories - LAV